What is the recommended Danuglipron dosage?

Danuglipron dosing varies by experience level. Beginners typically start at 10mg 2x daily, moderate users at 80mg 2x daily, and aggressive protocols use 120mg 2x daily.

How do you reconstitute Danuglipron?

Danuglipron comes as a pre-filled device — no reconstitution needed.

What is the half-life of Danuglipron?

The half-life of Danuglipron is ~6-8 hours. This determines how frequently you need to dose for consistent blood levels.

Danuglipron

Weight LossOralResearchGrade C~6-8 hours half-life

GLP-1 AgonistOralNon-PeptideSmall MoleculeWeight ManagementDiscontinuedPfizerType 2 Diabetes

Benefits

Demonstrated 5-13% placebo-adjusted weight loss in Phase 2b obesity trial at 26-32 weeks

Oral small-molecule format — no injections, no reconstitution needed

HbA1c reductions up to -1.16% vs placebo in type 2 diabetes trials

Does not require absorption enhancers or fasting restrictions (unlike oral semaglutide)

Fasting plasma glucose reductions up to -33 mg/dL vs placebo at higher doses

Comparable mechanism to injectable GLP-1 drugs but in pill form

Body weight reductions of -1.9 to -5.4 kg vs placebo at 12 weeks in T2D patients

Half-Life

~6-8 hours

Route

Oral

Frequency

2x Daily

Vial Sizes

120mg

BAC Water

Pre-filled

Safety Grade

Grade C

Open Danuglipron Dosage Calculator

Calculate exact syringe units for your vial and dose

About Danuglipron

Danuglipron (PF-06882961) was Pfizer's attempt to enter the GLP-1 weight loss market with an oral small-molecule drug that could compete with injectable semaglutide and tirzepatide. Unlike oral semaglutide (Rybelsus), which is still a peptide packaged with an absorption enhancer, danuglipron is a true small molecule — a non-peptide allosteric agonist of the GLP-1 receptor that survives the GI tract on its own. The Phase 2b trial in adults with obesity (626 participants) demonstrated meaningful weight loss, with placebo-adjusted reductions ranging from -5.0% to -12.9% at 26-32 weeks depending on dose. In type 2 diabetes trials, HbA1c reductions reached -1.16% versus placebo at the highest dose, with significant fasting glucose improvements. These are competitive numbers on paper. The problem was tolerability. Across all doses, more than 50% of participants discontinued treatment — compared to roughly 40% on placebo. About 38% dropped out specifically due to adverse events, mostly GI-related (nausea in 20-48% of participants, vomiting in 18-41%). The short half-life of approximately 6-8 hours meant twice-daily dosing, which compounded the tolerability issue. Pfizer pivoted to developing a once-daily extended-release formulation that met pharmacokinetic targets, but before it could reach Phase 3, a single participant in a dose-optimization study showed elevated liver enzymes consistent with potential drug-induced liver injury. Although the participant was asymptomatic and recovered after stopping the drug, and although liver enzyme elevations across the broader 1,400-person safety database were in line with approved GLP-1 agents, Pfizer chose to discontinue all danuglipron development in April 2025 after consulting with regulators. Danuglipron remains an instructive case in the oral GLP-1 space. Its clinical data showed that small-molecule GLP-1 agonism can produce weight loss comparable to injectable therapies, but the tolerability bar and safety requirements are high. Researchers may encounter it in literature comparisons with orforglipron, which ultimately succeeded where danuglipron did not.

Who Should Consider Danuglipron

Was under development for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with comorbidities
Adults with type 2 diabetes seeking oral GLP-1 options (Phase 2b data only)
Researchers studying oral small-molecule GLP-1 receptor agonism
Those comparing oral GLP-1 drug candidates (danuglipron vs orforglipron vs oral semaglutide)

How Danuglipron Works

Danuglipron is a non-peptide, small-molecule allosteric agonist of the glucagon-like peptide-1 (GLP-1) receptor. It binds to an allosteric site distinct from the orthosteric pocket where native GLP-1 and peptide-based agonists like semaglutide bind. By stabilizing an active conformation of the receptor, danuglipron triggers the same downstream signaling cascade as endogenous GLP-1: activation of Gs-protein-coupled pathways that increase intracellular cAMP, leading to glucose-dependent insulin secretion from pancreatic beta cells, suppression of glucagon release from alpha cells, delayed gastric emptying, and central appetite suppression via hypothalamic and brainstem GLP-1 receptors. As a small molecule (molecular weight approximately 584 g/mol), danuglipron is resistant to proteolytic degradation in the GI tract and is orally bioavailable without the absorption enhancers required by peptide-based oral GLP-1 drugs like semaglutide (Rybelsus). It can be taken with or without food — pharmacokinetic studies showed similar plasma exposure in fed versus fasted states. The compound is primarily metabolized through hepatic pathways, with a half-life of approximately 6-8 hours in humans. This short half-life compared to injectable GLP-1 agonists (semaglutide: ~7 days, liraglutide: ~13 hours) is the reason twice-daily dosing was necessary, and it was one of the key limitations Pfizer was trying to address with an extended-release formulation.

What to Expect

Weeks 1-4

Dose escalation phase starting from low doses (2.5-10 mg BID). GI side effects most pronounced during this period — nausea, vomiting, and dyspepsia were commonly reported. Modest appetite suppression may begin. Minimal weight change expected.

Weeks 5-12

Escalation toward target dose (80-120 mg BID). Phase 2 T2D data showed HbA1c reductions of approximately -1% and body weight reductions of -1.9 to -5.4 kg vs placebo at 12-16 weeks. GI side effects may persist or worsen with dose increases.

Weeks 13-26

Continued weight loss at target dose. Phase 2b obesity trial showed placebo-adjusted weight loss of -5% to -9.5% at 26 weeks. However, over 50% of participants had discontinued by this point in trials, primarily due to GI adverse events.

Weeks 27-32

Maximum observed efficacy window in Phase 2b. Placebo-adjusted weight loss reached -8% to -13% at 32 weeks in the highest dose groups among those who remained on treatment — though this reflects a survivorship bias given the high dropout rates.

Dosing Protocol

Level	Dose / Injection	Frequency
Beginner	10mg	2x Daily
Moderate	80mg	2x Daily
Aggressive	120mg	2x Daily

Note: Danuglipron (PF-06882961) is an oral small-molecule GLP-1 receptor agonist — not a peptide — developed by Pfizer. Development was discontinued in April 2025 after a single participant in a dose-optimization study experienced potential drug-induced liver injury (resolved after stopping the drug). Twice-daily dosing was required due to the short ~6-8 hour half-life, though Pfizer was developing an extended-release once-daily formulation before discontinuation. No reconstitution needed — oral tablet. Phase 2b data showed significant weight loss but very high discontinuation rates (>50% across all doses).

How to Inject Danuglipron

Note: Danuglipron development was discontinued in April 2025 — there is no approved dosing regimen. In Phase 2b clinical trials, danuglipron was administered as an oral tablet taken twice daily, with dose escalation from lower starting doses (2.5 mg BID) up to target doses of 80-120 mg BID over several weeks. The drug can be taken with or without food. In the type 2 diabetes Phase 2b trial, doses of 2.5, 10, 40, 80, and 120 mg were studied twice daily for 16 weeks. Slow dose escalation was used to manage GI tolerability, though discontinuation rates remained high across all dose groups.

Cycling Protocol

On Period

32 weeks

Off Period

0 weeks

Development discontinued — no approved dosing protocol exists. Phase 2b studies used continuous twice-daily dosing for 26-32 weeks with dose escalation over the first several weeks. The intended clinical use was continuous long-term treatment, similar to other GLP-1 agonists.

Pharmacokinetics

Half-Life

Bioavailability

Oral: not formally published; similar exposure in fed vs fasted states indicates food-independent absorption

Tmax

~1-4 hours

Data Confidence

moderate

Source: Saxena et al. Phase 1 MAD study (PMID 34127852); ~6-8 hour terminal half-life necessitating twice-daily dosing

Pharmacokinetics — Active Dose Over Time

Loading the interactive decay curve.

Side Effects

The GI side effect burden was the primary clinical limitation of danuglipron and a major contributor to its discontinuation. Nausea was reported in 20-48% of participants across dose groups versus 12.5% on placebo. Vomiting occurred in 18-41% of danuglipron groups. Diarrhea, dyspepsia, decreased appetite, and abdominal pain were also common. Discontinuation rates due to adverse events reached approximately 38% — far higher than placebo and higher than most approved GLP-1 drugs. The most significant safety signal was potential drug-induced liver injury (DILI) in a single participant during a dose-optimization study, presenting as elevated liver enzymes that resolved after stopping treatment. While the overall rate of liver enzyme elevations across the 1,400+ participant database was similar to approved GLP-1 agents, this single DILI case, combined with regulatory input, led Pfizer to halt development. Heart rate increases were observed at Day 28 in Phase 1 data, though no serious cardiac events occurred.

Contraindications

Development discontinued — not available for clinical use
History of drug-induced liver injury or significant hepatic impairment
Personal or family history of medullary thyroid carcinoma (GLP-1 class concern)
Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
Pregnancy or planning to become pregnant (no reproductive safety data)
Known hypersensitivity to danuglipron or any excipient
Concurrent use with other GLP-1 receptor agonists

Drug Interactions

Hepatically metabolized — potential interactions with CYP enzyme inhibitors and inducers (specific CYP isoforms not fully characterized in published data)
Insulin and sulfonylureas — increased hypoglycemia risk when combined with GLP-1 agonists
Oral medications affected by delayed gastric emptying — GLP-1 agonism slows gastric motility, potentially altering absorption of co-administered drugs
Hepatotoxic medications — given the DILI signal, theoretical additive risk with other hepatotoxic agents (acetaminophen at high doses, statins, certain antibiotics)
No formal drug interaction studies were published before discontinuation